Dong-A Pharmaceutical (CEO Shin-Ho Kang) announced on its acquisition of the Certificate of Suitability
(COS) of Europe for its anti-cancer treatment, Epirubicin® Hydrochloride, on June 21.




Epirubicin® HCI is the raw material for the anti-cancer drugs of Anthracyline, and has a mechanism of
controlling the nucleoside by combining with the DNA. It is the second-generation anti-cancer treatment which
improved the side effects of doxorubicin, the first-generation one, and is vastly used to treat breast cancer,
gastric cancer and lung cancer.




Currently, the items acquiring Europe’s COS in Korea are mostly antibiotics and antibacterial drugs. As
Epirubicin® HCI has acquired Europe’s COS, it would play a pivotal role in its exporting anti-cancer
ingredients. This can be interpreted to mean that Dong-A Pharmaceutical has made inroads into the European
market with the acquisition, forecast to enjoy sales of over USD three million per annum throughout the world
including Brazil, India, Taiwan and Australia.






# # #




About Dong-A Pharmaceutical

Dong-A is Korea’s leading pharmaceutical company. Based on its corporate philosophy that the greatest value
is life, Dong-A strives to be a responsible corporate citizen that contributes to the health and welfare of
humankind. Over the past 42 years, Dong-A has maintained a reputation as a trustworthy producer of quality
pharmaceutical products, and has risen to become the number one drug company in Korea. It is expanding its
overseas presence on the strength of its new drug and biopharmaceutical products. Dong-A Socio Group
includes Dong-A Otsuka, a beverage company, and Yongma Logis, a 3PL specialized company, and other
subsidiaries.




COS (Certification of Suitability of Monographs of the European Pharmacopoeia)

As an officinal quality certification of Europe, it confirms the suitability of the quality specification within the
European pharmacopoeia through the screening of EDQM (European Directorate for the Quality of Medicines),
the managing institution to manage the European pharmacopoeia, on a given product’s production and quality.